Business
Biodesix provides lung diagnostic testing and development services, with five blood-based tests used by healthcare providers and services for biopharma and diagnostics customers.
Biodesix grew lung-diagnostic revenue, narrowed losses and cash burn, but debt rose and equity turned negative.
The read at a glance✓ Audited against SEC data
- Business mix — Lung diagnostics and development servicesNote
- Revenue — Revenue rose 24.1%OK
- Losses — Net loss narrowed 17.9%OK
- Cash — Free cash flow improved 54.6%OK
- Balance sheet — Equity turned negative; debt roseWatch
- Insiders — Large purchases, but 25 salesNote
- Accounting — Altman-Z distress; Beneish-M clean; earnings-quality safeWatch
Where the revenue comes from
Fiscal 2025, as BIODESIX INC reports it. History and quarterly detail are in the app.
- Diagnostic Tests$79.2M
- Development Services$9.3M
Leadership changes
From BIODESIX INC's own filings, the day they're filed.
- Charles Watts · member · departureeff. 2025-04-15
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-04
- 10-Q · Quarterly report2026-05-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIODESIX INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.